Crizotinib is a first-in-class, orally available multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) that is locally advanced or metastatic [1]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.